Deepcell wins MICCAI 2021 Startup Village Pitch competition to advance cellular imaging through AI
MENLO PARK, Calif .– (COMMERCIAL THREAD) – Deepcell, a life sciences company pioneering the classification and isolation of AI-powered cells for cell biology and translational research, today announced that the company has received the 2021 award from the Startup Village of the prestigious company MICCAI at 24e Annual International Conference on Medical Informatics and Computer Assisted Intervention. Deepcell was recognized as the winner for its innovation in the application of AI to images of cells for biological research applications.
Deepcell was created from Stanford University in 2017 to reinvent single-cell analysis by creating a new quantitative dimension of cell morphology. Since then, the company has developed its AI-based technology to characterize, identify and sort cells based on visual characteristics.
“Deepcell is pioneering an approach to apply advanced computer image processing to living cells in a way that has never been done before,” said Mahyar Salek, co-founder and chief technology officer of Deepcell. “Winning the MICCAI award is a powerful endorsement of what Deepcell is doing to advance cell biology with our proprietary microfluidic and imaging system and deep learning models for cell characterization. Our new platform is designed to help unlock more in-depth biological information that is relevant to basic and translational research and future clinical applications. ”
At the MICCAI conference, which attracts leading biomedical scientists, engineers and clinicians, the judges evaluated Deepcell in a face-to-face competition of 10 finalist startups competing in front of audiences from around the world for one of the most prestigious awards in the world. field of medical imaging and AI. Deepcell received the highest average score in all categories including technological advancements, potential impact, accessibility and relevance to the MICCAI mission.
The company continues to increase its traction. Deepcell is expanding its partnerships with major academic centers and the biopharmaceutical industry, while continuing to present data at scientific conferences. The company also continues to build the industry’s largest repository of cellular images and associated computational-defined cellular visual characteristics.
For more information on Deepcell, visit www.deepcell.com.
Deepcell helps advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver new insights through unprecedented insight into cell biology. Released from Stanford University in 2017, the company created a unique microfluidics-based technology that uses lifelong learning AI to rank cells based on detailed visual characteristics and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream analysis of a single cell and can be used to isolate virtually any type of cell, even those that occur at frequencies as low as one over one billion. The technology will initially be available as a service for use in translational research as well as in diagnosis and therapeutic development. Deepcell is a privately held company based in Menlo Park, California. For more information, please visit deepcellbio.com.